Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012096989> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2012096989 abstract "Previously, pre‐clinical dose finding tolerance study in a human xenograft pancreatic cancer model of intravenous liposomal curcumin determined 20 mg/kg TIW was to be the optimum dose and schedule for anticancer activity. Follow up pharmacokinetic and dose finding studies in a health rat model evaluated doses up to 40 mg/kg was not associated with weight loss, hematological, serologic, or dose‐limiting toxicity. In canine model, a single‐dose finding tolerance study ranging from 2 mg/kg up to 40 mg/kg revealed the maximum tolerated dose (MTD) of liposomal curcumin to be 20 mg/kg or 540 uMol/L of curcumin maximal blood concentration. Toxicity observed at this dose level was characterized by a brief single episode of reversible hematuria. The dose limiting toxicity was observed at a single dose of 40 mg/kg of liposomal curcumin. Following dose on day 1, life threatening toxicity followed within 48 hours with the dogs exhibiting irreversible acute hemolysis with hematuria, over 60% blood loss, and associated serologic abnormalities. A control cohort of dogs infused with the same quantity of liposome contained in the 40/mg/kg dose was without ensuing toxicity. These changes suggest the mechanism of hemolysis following 40mg/kg curcumin is due to an oxidant effect. Following acute hemolysis, the iron chelation activity of curcumin could contribute to unremitting anemia by blocking iron reutilization. In conclusion, at concentrations below the canine MTD of 20 mg/kg, curcumin acts as an anti‐oxidant, and acts as a pro‐oxidant at higher concentrations. The disparity between rodent and canine sensitivity to liposomal curcumin may be due to species differences in pharmacokinetics and/or curcumin metabolism. Ongoing study will define liposomal curcumin pharmacokinetic parameters at the MTD in canine mode as well define tolerability of multiple dosing in dogs. In addition hematological studies are being conducted to determine the mechanism of hemolysis that was observed at higher dose levels and identify potential biomarkers for predicting toxicity. Preliminary data suggests liposomal curcumin will have promising anticancer activity. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A29." @default.
- W2012096989 created "2016-06-24" @default.
- W2012096989 creator A5031816138 @default.
- W2012096989 creator A5032139634 @default.
- W2012096989 creator A5041473101 @default.
- W2012096989 creator A5052309533 @default.
- W2012096989 creator A5090997052 @default.
- W2012096989 date "2009-12-10" @default.
- W2012096989 modified "2023-09-26" @default.
- W2012096989 title "Abstract A29: Development of liposomal curcumin as a new potential anticancer agent" @default.
- W2012096989 doi "https://doi.org/10.1158/1535-7163.targ-09-a29" @default.
- W2012096989 hasPublicationYear "2009" @default.
- W2012096989 type Work @default.
- W2012096989 sameAs 2012096989 @default.
- W2012096989 citedByCount "0" @default.
- W2012096989 crossrefType "proceedings-article" @default.
- W2012096989 hasAuthorship W2012096989A5031816138 @default.
- W2012096989 hasAuthorship W2012096989A5032139634 @default.
- W2012096989 hasAuthorship W2012096989A5041473101 @default.
- W2012096989 hasAuthorship W2012096989A5052309533 @default.
- W2012096989 hasAuthorship W2012096989A5090997052 @default.
- W2012096989 hasConcept C112705442 @default.
- W2012096989 hasConcept C116263406 @default.
- W2012096989 hasConcept C126322002 @default.
- W2012096989 hasConcept C185154212 @default.
- W2012096989 hasConcept C185592680 @default.
- W2012096989 hasConcept C2778250585 @default.
- W2012096989 hasConcept C2779902561 @default.
- W2012096989 hasConcept C29730261 @default.
- W2012096989 hasConcept C55493867 @default.
- W2012096989 hasConcept C71924100 @default.
- W2012096989 hasConcept C98274493 @default.
- W2012096989 hasConceptScore W2012096989C112705442 @default.
- W2012096989 hasConceptScore W2012096989C116263406 @default.
- W2012096989 hasConceptScore W2012096989C126322002 @default.
- W2012096989 hasConceptScore W2012096989C185154212 @default.
- W2012096989 hasConceptScore W2012096989C185592680 @default.
- W2012096989 hasConceptScore W2012096989C2778250585 @default.
- W2012096989 hasConceptScore W2012096989C2779902561 @default.
- W2012096989 hasConceptScore W2012096989C29730261 @default.
- W2012096989 hasConceptScore W2012096989C55493867 @default.
- W2012096989 hasConceptScore W2012096989C71924100 @default.
- W2012096989 hasConceptScore W2012096989C98274493 @default.
- W2012096989 hasLocation W20120969891 @default.
- W2012096989 hasOpenAccess W2012096989 @default.
- W2012096989 hasPrimaryLocation W20120969891 @default.
- W2012096989 hasRelatedWork W1502385370 @default.
- W2012096989 hasRelatedWork W1976543334 @default.
- W2012096989 hasRelatedWork W1998054889 @default.
- W2012096989 hasRelatedWork W2011631594 @default.
- W2012096989 hasRelatedWork W2016299124 @default.
- W2012096989 hasRelatedWork W2040569675 @default.
- W2012096989 hasRelatedWork W2060143541 @default.
- W2012096989 hasRelatedWork W620000789 @default.
- W2012096989 hasRelatedWork W644076287 @default.
- W2012096989 hasRelatedWork W1029343334 @default.
- W2012096989 hasRelatedWork W1480094002 @default.
- W2012096989 hasRelatedWork W1618387553 @default.
- W2012096989 hasRelatedWork W1637112493 @default.
- W2012096989 hasRelatedWork W1725498906 @default.
- W2012096989 hasRelatedWork W1760462969 @default.
- W2012096989 hasRelatedWork W1823867163 @default.
- W2012096989 hasRelatedWork W1872105060 @default.
- W2012096989 hasRelatedWork W1876297369 @default.
- W2012096989 hasRelatedWork W1935478627 @default.
- W2012096989 hasRelatedWork W1949907703 @default.
- W2012096989 isParatext "false" @default.
- W2012096989 isRetracted "false" @default.
- W2012096989 magId "2012096989" @default.
- W2012096989 workType "article" @default.